- Abu Dhabi Will Aid Debt-Fraught Dubai 'Case by Case'
- Banks With The Biggest Exposure to The UAE
- Dubai's Debt Woes Signal New Era for Creditors
- Next Week: Cash In Now Or Wait For A Santa Rally?
- Dubai Stock Selloff May Bring Buying Opportunity
- Longer Lines, Fuller Carts This Black Friday
- Big US Banks May Be Forced to Raise Capital: Bove
- Bank of America Amends Pay for Senior Executives
- Tiger Woods Out of Hospital After Accident
- U.S. Stocks Fall on Dubai Worries
- Black Friday at Best Buy
- Strategists on Dubai: Avoid 'Rash Moves' Now
- Longer Lines, Fuller Carts This Black Friday
- Dubai Stock Market Fear Has 'Legs': Dennis Gartman
- Obama's Emission Reduction Pledge Paints Future for Autos
- Is Super Bowl Halftime Act Too Old?
- Surprising Options Trades in TiVo Shares
- EA Sports Hopes to Pump Up Sales Through Pop-Up Locations
- Administration plans new efforts on foreclosures
- Leaders say momentum building on climate change
- Cars burned, windows broken at trade protest
- Police tap into ‘text-a-tip’ programs
- Text-a-Tip programs allow tipsters to help police
- Is Dubai Abu Dhabi's case of too big to fail?
- For stars, high-tech gaffes hard to hide
- Bernanke makes case for strong Fed role on banks
- GM says production at Ohio plant to end Jan. 29
WASHINGTON - Federal health officials are adding their sternest warning to a heartburn drug from Wyeth that has been linked to muscle spasms.
The Food and Drug Administration said Wyeth's pill Reglan has been shown to cause spasms and tics when used for long periods of time or at high doses. The agency is requiring both Wyeth and generic drugmakers to add a black box warning, the most serious type available, to their products.
Manufacturers also will be required to distribute medication safety guides to patients.
The drug's current labeling already mentions risks of developing the spasms, called dykinesia, but the agency's action Thursday elevates the warning to the top of the label. Reglan, known generically as metoclopramide, comes in a variety forms, including injections and edible syrups. The drug works by speeding up the muscles used in digestion and relieving painful stomach acid reflux.
More than 2 million U.S. patients use the drugs, according to the FDA.
"The chronic use of metoclopramide therapy should be avoided in all but rare vases where the benefit is believed to outweigh the risk," said Dr. Janet Woodcock, director of FDA's drug center.
Regulators said patients who face the greatest risks include the elderly, especially women, and those who have been taking the drug for more than three months.
The agency based its decision on recently published studies suggesting metoclopramide is the leading cause of pharmaceutical-related movement disorders.
Wyeth representatives had no immediate comment Thursday afternoon. The Madison, N.J.-based company recently was acquired in a $68 billion deal by Pfizer, the world's largest drugmaker.
- These four sectors will be the next to lead the market.
- Zhu Zhu Pets are this year's must-have toy, fetching $40 or more on eBay.
- From the why-didn’t-I-think-of-that file, we present Jason Sadler, a man whose job is wearing T-shirts.
- It may be the most unusual guide to business you'll read.
- Shopping for a gadget hound? The choices can be baffling. Here are a few that should be a hit.
- "The Who" will be the halftime act for Super Bowl XLIV on Feb. 7 in Miami. Is the NFL behind the times?








